Aier Eye Hospital (300015) Stock Price, Fundamentals & Analysis

What 300015 does

Aier Eye Hospital (300015) is a stock listed on the Shenzhen Stock Exchange in the Healthcare sector, specifically the Medical Care Facilities industry. The company operates as an ophthalmic medical group, offering diagnosis and treatment of various eye diseases, surgical services, medical optometry, and lens fitting for conditions such as fundus diseases, glaucoma, and cataract. It also provides training courses for procedures including cataract cases, ICL surgery, and presbyopia surgery. Founded in 2002 and headquartered in Changsha, China, Aier Eye Hospital operates across China, Hong Kong, Europe, the United States, and Southeast Asia.

Key numbers explained

• 7.91 CNY is the current price, representing the cost of one share in the local currency.
• The -1.25% price change today shows the intraday movement relative to the previous close.
• A trailing P/E ratio of 29.3 indicates how much investors pay per unit of recent earnings; it is calculated by dividing the price by the trailing 12-month earnings per share of 0.27 CNY.
• The forward P/E ratio of 17.8 uses expected future earnings, offering a different view of valuation.
• The dividend yield of 2.28% shows the annual dividend as a percentage of the current price, with 29% of earnings paid out as dividends.
• The ex-dividend date is 17 iul. 2026, the date after which new buyers are no longer entitled to the upcoming dividend.
• A beta of 0.38 suggests the stock tends to be less volatile than the overall market.
• The 52-week range of 7.82 – 12.83 shows the lowest and highest traded prices over the past year, with the current price near the low end.

What to watch

Aier Eye Hospital operates in the healthcare sector, where regulatory changes, medical policy shifts, and public health trends can affect demand for ophthalmic services. As a Medical Care Facilities company listed on the Shenzhen Stock Exchange, it may be influenced by broader healthcare reforms and investment flows in the sector. Investors often compare it with peers such as China Resources Sanjiu Medical & Pharmaceutical (000999), Hualan Biological Engineering (002007), Shanghai RAAS Blood Products (002252), Chang Chun High and New Technology Industry (Group) (000661), Asymchem Laboratories (Tianjin) (002821), Pharmaron Beijing (300759), and Shijiazhuang Yiling Pharmaceutical (002603) to understand sector positioning. The stock's -36.3% price change over the last 52 weeks and its proximity to the 52-week low are worth monitoring as part of its recent price history.